FDA Review Questions Cardiac, Suicide Risks for Investigational Antipsychotic
WASHINGTON (MedPage Today) — Investigational antipsychotic drug sertindole (Serdolect) is effective at treating schizophrenia, but it may lead to sudden cardiac death, according to an FDA review.
Similar Posts on depression:
- FDA Review Questions Cardiac, Suicide Risks for Investigational Antipsychotic
- FDA Panel Recommends Limited Use of Investigational Antipsychotic
- FDA Approves Iloperidone for Schizophrenia
- APA: Inhaled Agent Loxapine Effective in Acute Agitation (CME/CE)
- FDA Concerned About Expanding Quetiapine Use for Mood Disorders
- Quick Pulse Before Exercise Linked to Death Risk
- APA: Novel Antipsychotic Promising for Schizophrenia (CME/CE)
- Research Links Depression To Cardiac Death In Women Without Known Heart Disease
- Depression can break your heart
- FDA Panel Splits on New Uses for Atypical Antipsychotic
